Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-04-21
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using its Recursion OS platform, automated labs, and proprietary data to discover and develop medicines internally and with pharma partners.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Is the Re-Rating Gate
This is a platform-biotech story with real non-linear upside, but only if early clinical success becomes repeatable translation. The next wave of FDA and Phase 1 evidence matters more than generic AI enthusiasm.

Analysis

Thesis
Recursion is a proof-gated AI biotech: if REC-4881 secures a workable registration path and at least one more internal program validates platform-to-clinic repeatability, the business can shift from lumpy collaboration revenue toward a higher-quality mix of product sales, milestones, royalties, and externally financed program vehicles by 2031.
Last Economy Alignment
Cheaper cognition helps Recursion because it owns data, labs, and drug assets rather than a fragile seat-software layer, but value capture still hinges on clinical and regulatory proof.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.1x (from 5 most recent analyses)
Reasoning
Today the stock is valued mainly on cash, platform option value, and one emerging clinical proof point. By 2031 the upside case is a cleaner revenue mix: one meaningful internal product, broader milestone and royalty streams, and more standardized platform monetization. That warrants a higher-quality multiple than a pure services biotech, but still below premium commercial biotech because proof, dilution, and regulatory risk do not disappear.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is not compute access; it is translation. Recursion must show that its data-and-lab engine can repeatedly produce clinically and regulatorily credible assets before runway pressure returns. If the next 12-18 months deliver a clear REC-4881 path plus a second internal proof point, the model improves sharply. If not, the company risks staying trapped between platform promise and expensive biotech reality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.56
They do not just sell software; they control proprietary biology data, automated labs, and drug programs that get better as AI gets cheaper. The flywheel is real, but it only compounds if more programs work in humans and with regulators.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.50
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case